E Seaman1, E T Goluboff, S Ross, I S Sawczuk. 1. J. Bentley Squier Urologic Clinic, Columbia-Presbyterian Medical Center, Department of Urology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
Abstract
OBJECTIVES: We assessed the frequency of bone metastases, their association with serum alkaline phosphatase (AP), and prognostic capabilities of AP in patients with renal cell carcinoma (RCC), using bone scan as the reference standard for diagnosis. METHODS: We conducted a retrospective review of patients with metastatic RCC treated with eitherautologous ex vivo activated T-lymphocytes and cimetidine (ALT) or cimetidine alone. RESULTS: Twenty-eight of 90 patients (31%) had evidence of bone metastases by bone scan. With 100 mg/ dL as the upper limit of normal, 11 of 28 (39%) patients with bone metastases had normal AP levels. Of these 11 patients, 8 had bone pain. Of the 3 asymptomatic patients with bone metastasis and normal AP levels, only 1 had bone as the only site of metastasis and would have been incorrectly staged without the scan. Patients with bone metastases had a significantly shorter median survival than those without bone metastases (13.8 versus 25.3 months; P < 0.05). Among patients without bone metastases who had elevated AP levels, those treated with ALT had significantly longer median survivals than those treated with cimetidine alone (27.6 versus 14.5 months; P < 0.05). Overall, patients treated with ALT had a significantly longer median survival than the ones treated only with cimetidine (21 versus 8.5 months; P < 0.05). Overall, the median survival for patients with elevated AP levels (10 months) was not significantly different from that of those with normal AP levels (13 months). CONCLUSIONS: In a high-risk group of patients with metastatic RCC, 31% had bone metastases. Elevated AP levels, the presence of bone pain, or the presence of other metastases correctly predicted bone metastasis in all but 1 patient. A bone scan may safely be omitted in patients with RCC, normal AP levels, and no bone pain. However, AP elevation itself had little prognostic capability in these patients.
RCT Entities:
OBJECTIVES: We assessed the frequency of bone metastases, their association with serum alkaline phosphatase (AP), and prognostic capabilities of AP in patients with renal cell carcinoma (RCC), using bone scan as the reference standard for diagnosis. METHODS: We conducted a retrospective review of patients with metastatic RCC treated with either autologous ex vivo activated T-lymphocytes and cimetidine (ALT) or cimetidine alone. RESULTS: Twenty-eight of 90 patients (31%) had evidence of bone metastases by bone scan. With 100 mg/ dL as the upper limit of normal, 11 of 28 (39%) patients with bone metastases had normal AP levels. Of these 11 patients, 8 had bone pain. Of the 3 asymptomatic patients with bone metastasis and normal AP levels, only 1 had bone as the only site of metastasis and would have been incorrectly staged without the scan. Patients with bone metastases had a significantly shorter median survival than those without bone metastases (13.8 versus 25.3 months; P < 0.05). Among patients without bone metastases who had elevated AP levels, those treated with ALT had significantly longer median survivals than those treated with cimetidine alone (27.6 versus 14.5 months; P < 0.05). Overall, patients treated with ALT had a significantly longer median survival than the ones treated only with cimetidine (21 versus 8.5 months; P < 0.05). Overall, the median survival for patients with elevated AP levels (10 months) was not significantly different from that of those with normal AP levels (13 months). CONCLUSIONS: In a high-risk group of patients with metastatic RCC, 31% had bone metastases. Elevated AP levels, the presence of bone pain, or the presence of other metastases correctly predicted bone metastasis in all but 1 patient. A bone scan may safely be omitted in patients with RCC, normal AP levels, and no bone pain. However, AP elevation itself had little prognostic capability in these patients.
Authors: O Annibali; M T Petrucci; D Santini; V Bongarzoni; M Russano; F Pisani; O Venditti; F Pantano; A Rago; A Siniscalchi; E Cerchiara; L Franceschini; L De Rosa; M Mariani; S Andriani; L Cudillo; M Garcia; M Cantonetti; S Mohamed; B Anaclerico; T Caravita; F Stocchi; G Cimino; S Gumenyuk; F Vozella; G Avvisati Journal: J Bone Oncol Date: 2020-11-18 Impact factor: 4.072
Authors: Andrey Soares; Fernando Sabino Marques Monteiro; Fernando Cotait Maluf; Diogo Assed Bastos; Denis Leonardo Jardim; André Deeke Sasse; Adriano Gonçalves E Silva; André P Fay; Diogo Augusto Rodrigues da Rosa; Evanius Wierman; Fabio Kater; Fabio A Schutz; Fernando Nunes Galvão de Oliveira; Igor Alexandre Protzner Morbeck; José Augusto Rinck; Karine Martins da Trindade; Manuel Caitano Maia; Vinicius Carrera Souza; Deusdedit Cortez Vieira da Silva Neto; Felipe de Almeida E Paula; Fernando Korkes; Gustavo Franco Carvalhal; Lucas Nogueira; Roni de Carvalho Fernandes; Rodolfo Borges Dos Reis; Wagner Eduardo Matheus; Wilson Francisco Schreiner Busato; Walter Henriques da Costa; Stênio de Cássio Zequi Journal: J Cancer Res Clin Oncol Date: 2020-05-14 Impact factor: 4.553